Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 15/20 | 0.47 |
| ▸ | HTR2A | P28223 | 12/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23927851 | 1.00 | HTR2C (0.47) | HTR2CHTR2APRMT5CYP1A2CYP3A4 | |
| SCHEMBL23956077 | 1.00 | HTR2C (0.47) | HTR2CHTR2APRMT5CYP1A2CYP3A4 | |
| SCHEMBL29780356 | 1.00 | HTR2C (0.47) | HTR2CHTR2APRMT5CYP1A2CYP3A4 | |
| SCHEMBL23927891 | 0.90 | HTR2C (0.44) | HTR2CHTR2APRMT5CYP1A2CYP3A4 | |
| SCHEMBL23927893 | 0.90 | HTR2C (0.44) | HTR2CHTR2APRMT5CYP1A2CYP3A4 | |
| SCHEMBL29780336 | 0.90 | HTR2C (0.44) | HTR2CHTR2APRMT5CYP1A2CYP3A4 | |
| SCHEMBL23927899 | 0.89 | HTR2C (0.51) | HTR2CHTR2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL23927839 | 0.89 | HTR2C (0.51) | HTR2CHTR2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL23927838 | 0.89 | HTR2C (0.51) | HTR2CHTR2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL23927903 | 0.89 | HTR2C (0.51) | HTR2CHTR2ACYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11254640-B2 | N-substituted indoles and other heterocycles for treating brain disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-02-22 | — | — | US | disclosed |
| US-20210332012-A1 | N-SUBSTITUTED INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA CORPORATION | 2021-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254640-B2 | N-substituted indoles and other heterocycles for treating brain disorders | TPH2, AANAT, HTR2C | HTR2C 3/4885HTR2A 5/4885PRMT5 796/4885 |
| US-20210332012-A1 | N-SUBSTITUTED INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | TPH2, AANAT, HTR2C | HTR2C 3/4885HTR2A 5/4885PRMT5 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.